Principal Investigator: Boadie Dunlop, MD
Population: Adults aged 18-65 with depression who haven’t responded to at least 1, but no more than 2 antidepressants in their current episode of depression.
Summary: Patients who enroll in this 18-week study will receive treatment with an FDA-approved antidepressant and will be randomly assigned to either receive placebo or cariprazine (an atypical antipsychotic) in addition to the antidepressant. Patients will always be receiving an active medication throughout the study. The initial screening visit is about 3 hours and the visits after that are 1hr-1.5hrs. There is the possibility for a 6-month extension treatment phase after the 18-week study. Study will provide compensation.
Procedure: Physical exams, blood draws, eye exams.